COCP

Price & events

Pipeline stages · 1 programs

Pipeline · 2 trials · 1 upcoming

Catalyst news & presentations · 11

• April 27–May 1, 2026conferencedata presentationsecondaryPhase 1CDI-988 · Presentation of ongoing Phase 1b challenge study data at ICAR2026.SEC 8-K
• first quarter of 2026trial initiationsecondaryPhase 1CDI-988 · Enrollment expected to begin in Q1 2026 for Phase 1b human challenge study.SEC 8-K
• later in 2025trial initiationsecondaryCDI-988 · Initiate human challenge study in norovirus-infected subjectsSEC 8-K
• Wednesday, December 3, 2025 at 10:00 am Eastern timeconferencedata presentationsecondaryJames Martin presents company overview and clinical progress update at Noble Capital Markets 21st Emerging Growth Equity Conference.SEC 8-K
• 2025-10-28partnershipCompleted private placement with four insider investors for $1.03MSEC 8-K
• 2025-10-27partnershipinfluenza A/B antiviral candidate · Received approximately $500,000 SBIR Phase I award from NIH/NIAID to advance development of oral broad-spectrum influenza inhibitorSEC 8-K
• 2025-09-01fda agreementCDI-988 · FDA issued Study May Proceed Letter for Phase 1b challenge study.SEC 8-K
• current quartertrial initiationsecondaryPhase 1CDI-988 · Begin enrollment in higher-dose (1,200 mg for 5 days) cohort of ongoing Phase 1 studySEC 8-K
• late 2024 or early 2025readoutPhase 1CDI-988 · Topline results from Phase 1 multiple-ascending cohortsSEC 8-K
• by the end of 2024readoutPhase 2CC-42344 · Topline safety and tolerability results from Phase 2a human challenge studySEC 8-K
• fourth quarter of this yeartrial initiationsecondaryPhase 1CDI-988 · Initiate MAD cohorts of Phase 1 study for oral pan-viral protease inhibitor CDI-988.SEC 8-K